Teva Pharmaceuticals Acquires Neuroscience Assets

The $57.5 million purchase grants Teva rights to IGALMI and an investigational film for treating acute patient agitation.

Updated on Oct. 27, 2026 in Healthcare

Teva Pharmaceuticals Acquires Neuroscience Assets

Live Poll

Do you believe large pharmaceutical acquisitions generally lead to better outcomes for everyday patients?

Teva Pharmaceuticals has completed a $57.5 million acquisition of neuroscience assets from BioXcel Therapeutics via a court-supervised Section 363 sale. The deal grants Teva worldwide rights to the FDA-approved IGALMI and the investigational agitation treatment BXCL501.

Why it matters

The acquisition aligns with Teva's Pivot to Growth strategy by capturing assets for acute agitation, a condition affecting 25% to 40% of patients with schizophrenia or bipolar disorder. By securing these rights, Teva gains a pipeline candidate currently under FDA review for at-home use.

Teva Pharmaceuticals paid $57.5 million upfront to acquire neuroscience assets, with an additional $67.5 million in potential contingent payments. The acquisition aims to address agitation in patients with schizophrenia or bipolar disorder, a group estimated at 25% to 40% of the patient population.

The players

Teva Pharmaceuticals

A global pharmaceutical company headquartered in Israel that produces generic and specialty medicines with a focus on neuroscience and growth-oriented acquisitions.

BioXcel Therapeutics

A biopharmaceutical company that develops artificial intelligence-driven neuroscience and immuno-oncology treatments.

The details

The transaction was executed through a court-supervised sale under Section 363 of the U.S. Bankruptcy Code, which allows for the purchase of assets free and clear of certain liabilities. Teva gains full control over the commercial IGALMI sublingual film and the investigational BXCL501 product. The latter is currently submitted as a supplemental New Drug Application to the existing IGALMI NDA to expand clinical utility for at-home acute agitation treatment.

October 27, 2026: Teva announced the completion of the asset acquisition.
March 2026: Teva conducted market research on the prevalence of acute agitation.

Market Landscape

This acquisition follows the established pattern of using Section 363 of the U.S. Bankruptcy Code to acquire distressed pharmaceutical assets without assuming the seller's wider corporate liabilities. It signals a move by large-scale operators to consolidate specialized neuroscience assets during bankruptcy-related liquidations.

Operators in the pharmaceutical and specialty care space should monitor the FDA's decision on the supplemental New Drug Application for at-home use of BXCL501. This case highlights how distressed sales can provide established firms with late-stage R&D assets that bypass early development risks.

The takeaway

This deal underscores the utility of Section 363 sales as a strategic lever for scaling specialized treatment portfolios. Leaders should track the progress of the BXCL501 supplemental NDA, as its potential approval for at-home use could redefine market standards for acute agitation management.